Advanced search
Publication Cover
Current Medical Research and Opinion Volume 35, 2019 - Issue 9
Submit an article Journal homepage
1,052
Views
13
CrossRef citations to date
0
Altmetric
Oncology

Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia

Jorge E. CortesDepartment of Leukemia, MD Anderson Cancer Center, Houston, TX, USA;
,
Bogdan MuresanIngress-Health, Rotterdam, The Netherlands; Correspondence[email protected]
,
Carla MamoloPatient & Health Impact, Pfizer Inc., Groton, CT, USA; ORCID Iconhttp://orcid.org/0000-0001-5321-561X
ORCID Icon,
Joseph C. CappelleriGlobal Biometrics & Data Management, Pfizer Inc., Groton, CT, USA;
,
Rocco J. CrescenzoWorldwide Research & Development, Pfizer Inc., Walton Oaks, UK (at the time of this research);
,
Yun SuPatient & Health Impact, Pfizer Inc, New York, NY, USA (at the time of this research);
,
Carlo Gambacorti-PasseriniDepartment of Hematology, University of Milano Bicocca, Monza, Italy;
,
Bart HeegIngress-Health, Rotterdam, The Netherlands;
&
B. Douglas SmithDepartment of Oncology, John Hopkins University School of Medicine, Baltimore, MD, USA
 show all
Pages 1615-1622 | Received 23 Oct 2018, Accepted 05 Apr 2019, Published online: 15 May 2019

References

  • Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15:940–947.
  • Ishak KJ, Proskorovsky I, Benedict A. Simulation and matching-based approaches for indirect comparison of treatments. Pharmacoeconomics. 2015;33:537–549.
  • Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1–e34.
  • Shah P, Kantarjian H, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. JCO. 2008;26:3204–3212.
  • Shah N, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014;123:2317–2324.
  • Kantarjian H, Giles F, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117:1141–1145.
  • Giles FJ, Le Coutre PD, Pinilla-Ibarz J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013;27:107–112.
  • Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan–Meier estimate. Int J Ayurveda Res. 2010;1:274–278.
  • Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12:9.
  • Bendel RB, Afifi AA. Comparison of stopping rules in forward regression. J Am Stat Assoc. 1977;72:46–53.
  • Mickey J, Greenland S. A study of the impact of confounder-selection criteria on effect estimation. Am J Epidemiol. 1989;129:125–137.
  • Websitename [Statsdirect] [Internet] [cited 2018 Apr 26]. Available from: http://www.statsdirect.com/help/survival_analysis/cox_regression.htm
  • Uno H, Claggett B, Tian L, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014;32:22.
  • Uno H, Wittes J, Fu H, et al. Alternatives to hazard ratios for comparing the efficacy or safety of therapies in noninferiority studies. Ann Intern Med. 2015;163:127–134.
  • Phillippo DM, Ades AE, Dias S, et al. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE. Report by the Decision Support Unit; 2016. Available from: https://scharr.dept.shef.ac.uk/nicedsu/wp-content/uploads/sites/7/2017/05/Population-adjustment-TSD-FINAL.pdf
  • Haznedaroglu IC. Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations. Expert Opin Pharmacother. 2013;14:2005–2010.
  • Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121:4439–4442.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.